All CD70 reagents are produced in house and quality controlled, including 1 CD70 Antibody, 52 CD70 Gene, 6 CD70 Lysate, 6 CD70 Protein, 2 CD70 qPCR. All CD70 reagents are ready to use.
Recombinant CD70 proteins are expressed by HEK293 Cells with fusion tags as N-human IgG1-Fc, N-His, N-mouse IgG1-Fc, N-rabbit IgG-Fc.
CD70antibodies are validated with different applications, which are WB.
CD70cDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each CD70 of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.
CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clinical candidates.